

Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for Asthma and COPD Patients

Vicente Plaza, MD, PhD,¹ Concepción Fernández-Rodríguez, MD, PhD,² Carlos Melero, MD, PhD,³ Borja G. Cosío, MD, PhD,⁴ Luis Manuel Entrenas, MD, PhD,⁵ Luis Pérez de Llano, MD, PhD,⁶ Fernando Gutiérrez-Pereyra, MD,¹ Eduard Tarragona, MD,⁷ Rosa Palomino, MSc,⁸ and Antolín López-Viña, MD, PhD,⁹ on behalf of the TAI Study Group*

Abstract

Background: To validate the ‘Test of Adherence to Inhalers’ (TAI), a 12-item questionnaire designed to assess the adherence to inhalers in patients with COPD or asthma.

Methods: A total of 1009 patients with asthma or COPD participated in a cross-sectional multicenter study. Patients with electronic adherence $\geq 80\%$ were defined as adherents. Construct validity, internal validity, and criterion validity were evaluated. Self-reported adherence was compared with the Morisky-Green questionnaire.

Results: Factor analysis study demonstrated two factors, factor 1 was coincident with TAI patient domain (items 1 to 10) and factor 2 with TAI health-care professional domain (items 11 and 12). The Cronbach’s alpha was 0.860 and the test-retest reliability 0.883. TAI scores correlated with electronic adherence ($\rho=0.293$, $p=0.01$). According to the best cut-off for 10 items (score 50, area under the ROC curve 0.7), 569 (62.5%) patients were classified as non-adherents. The non-adherence behavior pattern was: erratic 527 (57.9%), deliberate 375 (41.2%), and unwitting 242 (26.6%) patients. As compared to Morisky-Green test, TAI showed better psychometric properties.

Conclusions: The TAI is a reliable and homogeneous questionnaire to identify easily non-adherence and to classify from a clinical perspective the barriers related to the use of inhalers in asthma and COPD.

Key words (MeSH terms): anti-asthmatic agents, administration and dosage; inhalers; medication adherence; medication non-adherence; questionnaires; pulmonary disease, chronic obstructive, drug therapy; validation studies

¹Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau. Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain.

²Facultad de Psicología, Universidad de Oviedo, Oviedo, Asturias, Spain.

³Pulmonology Department, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain.

⁴Department of Respiratory Medicine, Hospital Son Espases-IdISPa, Palma de Mallorca. CIBER Enfermedades Respiratorias (CIBERES), Spain.

⁵Pulmonology Department, Hospital Reina Sofía, Córdoba, Spain.

⁶Pulmonology Department, Hospital Universitario Lucus Augusti. Lugo, Spain.

⁷Medical Department, Chiesi Spain, L’Hospitalet de Llobregat, Barcelona, Spain. Spain.

⁸Àrea de investigació aplicada, GOC Networking, Barcelona, Spain.

⁹Pulmonology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

© The Author(s) 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

*TAI Study Group (investigators and participating centers by alphabetical order): Agüero Balbín, R (H. Universitario Marqués de Valdecilla, Cantabria); Alcázar Navarrete, B (H. Alta Resolución de Loja, Granada); Ali García, I (H. Infanta Leonor Vallecas, Madrid); Almonacid Sánchez, C (H. General Guadalajara); Alvaredo Martín, I (Centro de Salud Bañeza II, León); Álvarez Navascues, F (H. San Agustín, Asturias); Álvaro Álvarez, D (H. Universitario de Móstoles, Madrid); Andujar Espinosa, R (H. Universitario Virgen de la Arrixaca, Murcia); Ansola Zubiaurre, P (H. Universitario Cruces, Bizkaia); Antolín García, M (H. Virgen de la Concha, Zamora); Armedillo Muñoz, A (H. Universitario Puerto del Mar, Cádiz); Arranz Alonso, S (Servicio de Prevención, Madrid); Avilés Ingles, M (H. Reina Sofía, Murcia); Badimon Garrido, M (H. General de Valencia); Barcena Caamaño, M (Centro de Salud Novoa Santos, Orense); Barranco Sanz, P (H. Universitario La Paz, Madrid); Bazús, T (H. Universitario Central de Asturias); Bioque Rivera, J (H. Infanta Margarita, Córdoba); Bollo De Miguel, E (Complejo Asistencial Universitario de León); Bouza Álvarez, D (Centro de Salud Ventorrillo, La Coruña); Bravo Gutiérrez, F (H.

Santa Lucía, Murcia); Burches Baixauli, E (H. Clínico de Valencia); Bustamante Madariaga, V (H. Universitario Basurto, Bizkaia); Cabrera López, C (H. Universitario de Gran Canaria Dr. Negrín); Calle Rubio, M (H. Clínico San Carlos, Madrid); Calvo Corbella, E (Centro de Salud Universitario Pozuelo Estación, Madrid); Capelastegui Saiz, A (H. de Galdakao, Bizkaia); Carballada Gonzalez, F (H. Lucus Augusti, Lugo); Carretero Gracia, J (H. Universitario Miguel Servet, Zaragoza); Caruana Careaga, T (H. Universitario Puerta de Hierro, Madrid); Casas Maldonado, F (H. Universitario San Cecilio, Granada); Cassini Gómez De Cádiz, L (H. Universitario San Cecilio, Granada); Castillo Vizuete, J (Centro de Atención Primaria Jaume I, Barcelona); Cebollero Rivas, P (Complejo Hospitalario de Navarra); Centeno Etxebarrieta, E (H. San Eloy, Bizkaia); Chiner Vives, E (H. Universitario San Juan de Alicante); Cimas Hernando, J (Centro de Salud de Contruaces - Vega, Asturias); Cisneros Serrano, C (H. Universitario La Princesa, Madrid); Colás Sanz, C (H. Clínico Universitario Lozano Blesa, Zaragoza); Compán Bueno, M (H. Virgen Macarena, Sevilla); Conde Valero, A (H. Universitario San Cecilio, Granada); Contreras Porta, F (H. Universitario La Paz, Madrid); Corbacho Abelaira, M (Povisa, Pontevedra); Cordero Montero, P (H. Infanta Cristina, Badajoz); Costan Galicia, J (H. Clínico Universitario Lozano Blesa, Zaragoza); De Diego Damiá, A (H. Universitari La Fé, Valencia); De Higes Martínez, E (H. Universitario Fundación Alcorcón, Madrid); Delgado Romero, J (H. Virgen Macarena, Sevilla); Diego Roza, C (H. Arquitecto Marcide, La Coruña); Diez Fernández, F (Complejo Asistencial Universitario de León); Domenech Del Rio, A (H. Carlos Haya, Málaga); Domínguez Álvarez, M (Hospital del Mar - Parc de Salut Mar, Barcelona); Domínguez Juncal, L (Complejo Hospitalario Universitario, La Coruña); Domínguez Ortega, J (H. Universitario La Paz, Madrid); Entrenas, L (H. Universitario Reina Sofía, Córdoba); Espinosa De Los Monteros Garde, M (H. Virgen de La Salud, Toledo); Estirado Vera, C (Hospital del Mar - Parc de Salut Mar, Barcelona); Fernández González, M (H. Universitario Central de Asturias); Fernández Robledo, E (H. General de Tomelloso, Albacete); Fernández Tena, A (H. Universitario Central de Asturias); Fernández Villar, A (Complejo Hospitalario Universitario de Vigo); Figueira Gonçalves, J (H. Univ. Ntra. Sra. De Candelaria, Santa Cruz de Tenerife); Flor Escriche, X (Centro de Atención Primaria Chafarinas, Barcelona); Florido López, J (H. Universitario San Cecilio, Granada); Fluixá Carrascosa, C (Centro de Salud Valencia-Benimaçlet, Valencia); Galdiz Iturri, J (H. Universitario Cruces, Bizkaia); Garcia De Pedro, J (H. Universitario Gregorio Marañón, Madrid); García Marrón, M (H. de Cabueñes, Asturias); Garcia Rivero, J (H. de Laredo, Cantabria); García-Cosío, B (H. Son Espases, Baleares); García-Giralda Ruíz, L (Centro de Salud Murcia-Centro (San Juan)); Gil Adrados, A (Centro de Salud La Solana, Toledo); Gil Carbonell, J (H. General Universitario de Alicante); Gil Marín, B (H. Infanta Cristina, Madrid); Gimeno Peribáñez, M (Hospital de Palamós, Girona); Ginel Mendoza, L (Centro de Salud Ciudad Jardín, Málaga); Giner Donaire, J (H. de la Santa Creu i Sant Pau, Barcelona); Godoy Mayoral, R (Complejo Hospitalario Universitario de Albacete); Gómez Entrena, M (H. Infanta Elena, Huelva); Gómez Torrijos, E (H. General Universitario de Ciudad Real); González Barcala, F (H. Clínico Universitario, La Coruña); González Gutiérrez, M (H. de Mataró, Barcelona); González López, A (Complejo Hospitalario de Orense); González Vargas, F (H. Universitario Virgen de las Nieves, Granada); Guallar Ballester, J (H. General de Castellón); Gutiérrez Vall De Cabres, V (H. Universitario Dr. Peset y H. Universitario Casa Salud, Valencia); Hernández Fernández De Rojas, M (H. Universitari La Fé, Valencia); Hernández Flix, S (H. Universitari de Sant Joan); Hueto Pérez De Heredia, J (Complejo Hospitalario de Navarra); Igea Aznar, J (Clínica Alergoasma, Salamanca); Iglesias Heras, M (Complejo Asistencial de Ávila); Ignacio García, J (H. Quirón Marbella, Málaga); Iriarte Sotés, P (Complejo Hospitalario Universitario de Ferrol y Hospital Naval de Alergología, La Coruña); Lama Martínez, R (H. Universitario Reina Sofía, Córdoba); Laparra Galíndez, J (H. Universitario Donostia); Lázaro Asegurado, L (H. Universitario de Burgos); Levy Naón, A (H. Clínico Universitario de Málaga); Linares Asensio, M (H. Universitario Fundación Alcorcón, Madrid); Llorca Martínez, E (H. General de Elda, Alicante); López De Santa María Miro, E (H. Universitario Cruces, Bizkaia); López Viña, A (H. Universitario Puerta de Hierro, Madrid); Madueño Caro, A (Centro de Salud La Laguna, Cádiz); Maíz Carro, L (H. Ramón y Cajal, Madrid); Malia Alvarado, D (H. Universitario Los Arcos del Mar Menor, Murcia); Marin Tapia, A (H. Germans Trias i Pujol, Barcelona); Marina Malanda, N (H. Universitario Cruces, Bizkaia); Martín Serrano, C (H. General Universitario de Alicante); Martín Villasclaras, J (H. Regional Universitario Carlos Haya, Málaga); Martínez Carbonell, J (H. San Vicente, Alicante); Martínez González, C (H. Universitario Central de Asturias); Martínez Moragón, E (H. Universitario Dr. Peset, Valencia); Martínez Rivera, C (H. Universitari Germans Trias i Pujol, Barcelona); Martos Velasco, J (H. San Rafael, Barcelona); Mata Poyo, J (Centro de Salud de Tabara, Zamora); Mayoralas Alises, S (H. Ramón y Cajal, Madrid); Medina Gallardo, J (H. Universitario Virgen del Rocío y Centro Especialidades Dr. Fleming, Sevilla); Melero, C (H. Doce de Octubre, Madrid); Mengibar Vallejo, P (H. General de Baza, Granada); Merlos Navarro, S (H. Universitario Virgen de las Nieves, Granada); Miranda Páez, A (H. General de Málaga); Molina Paris, J (Centro de Salud Francia, Madrid); Morante Vélez, F (H. de la Santa. Creu i Sant Pau, Barcelona); Moreno Ancillo, A (H. Nuestra Señora del Prado, Toledo); Mosteiro Añón, M (Complejo Hospitalario Universitario de Vigo); Olaguibel Rivera, J (Centro de Salud Conde Oliveto, Navarra); Ortega Ruiz, F (H. Universitario Virgen del Rocío, Sevilla); Ortiz De Saracho Bobo, J (H. El Bjerzo, León); Pascual Gil, O (Centro de Salud de Guadalajara Sur); Pascual Lledó, J (H. General Universitario de Alicante); Pedro Pijoan, A (Área Básica de Salud Gaudí, Barcelona); Peiró Fàbregas, M (H. de la Santa. Creu i Sant Pau, Barcelona); Pellicer Císcar, C (H. Francesc de Borja, Valencia); Pérez Camo, I (H. Royo Villanova, Zaragoza); Pérez Chica, G (H. Médico-Quirúrgico de Jaén); Pérez De Llano, L (H. Universitario de Lugo); Pérez Rodríguez, A (H. Univ. Ntra. Sra. De Candelaria, Santa Cruz de Tenerife); Piedra Castro, R (Centro de Salud Azuqueca de Henares, Guadalajara); Plaza Moral, V (H. de Santa. Creu i Sant Pau, Barcelona); Puente Maestu, L (H. Universitario Gregorio Marañón, Madrid); Pueyo Bastida, A (H. Universitario de Burgos); Querol Borrás, J (H. Vega Baja, Alicante); Quintano Jiménez, J (Centro de Salud Lucena, Córdoba); Quiñones Higuero, N (H. Universitario Puerta de Hierro Majadahonda, Madrid); Quirce Gancedo, S (H. Universitario La Paz, Madrid); Ramón Capilla, M (H. General de Valencia); Ramos Barbón, D (H. de Santa. Creu i Sant Pau, Barcelona); Ramos González, J (Complejo Asistencial Universitario de Salamanca); Riesco Miranda, J (H. San Pedro de Alcántara, Cáceres); Rivera Ortún, M (H. Universitario Germans Trias i Pujol, Barcelona); Rodríguez González, J (H. Univ. Ntra. Sra. De Candelaria, Santa Cruz de Tenerife); Rodríguez Hermosa, J (H. Clínico San Carlos, Madrid); Rodríguez Pascual, L (H. Universitario de Burgos); Rodríguez Porres, M (Centro de Salud Bajo Asón, Cantabria); Roig Figueroa, V (H. Clínico Universitario de Valladolid); Rojas Box, J (H. Infanta Lusia, Sevilla); Román Rodríguez, M (Centro de Salud Son Pisa, Baleares); Romero Falcón, M (Centro Especialidades Dr. Fleming y H. Universitario Virgen del Rocío, Sevilla); Romero Ribate, D (H. Universitario La Paz, Madrid); Royo Prats, J (H. General de Castellón); Rubinstein Aguñín, P (H. General de Catalunya, Barcelona); Ruiz Hornillos, J (H. Universitario Infanta Elena, Madrid); Ruz García, A (H. Sant Joan Despí Moises Broggi, Barcelona); Sáez Roca, G (H. Virgen de las Nieves, Granada); Sala Cunill, A (H. Universitario Vall D'Hebron, Barcelona); Sánchez Berenguer, D (H. Municipal de Badalona, Barcelona); Sánchez Nieto, J (H. Morales Meseguer, Murcia); Sánchez Ruano, N (Centro de Atención Primaria Comte Borrell, Barcelona); Sanchez-Toril López, F (H. Arnau de Vilanova, Valencia); Sanjuán Sanchís, E (Centro de Atención Primaria María Bernades, Barcelona); Sans Torres, J (Consorti Sanitari de Terrassa, Barcelona); Sanz Sanz, P (H. Universitario Gregorio Marañón, Madrid); Sebastian Ariño, A (H. Clínico Universitario Lozano Blesa, Zaragoza); Serra Batlles, J (H. General de Vic, Barcelona); Serrano Pariente, J (H. Comarcal de Inca, Baleares); Sogo Sagardía, A (H. Universitario Parc Taulí, Barcelona); Sojo González, M (Complejo Hospitalario Cáceres); Soto Campos, J (H. de Jerez, Cádiz); Soto Jiménez, J (Centro de Salud Armunia, León); Soto Venegas, A (H. San Juan de La Cruz, Jaén); Tárrega Camarasa, J (H. General de Granollers, Barcelona); Torrejón Lázaro, M (H. de Santa. Creu i Sant Pau, Barcelona); Trigueros Carrero, J (Centro de Salud Menasalbas, Toledo); Urrutia Landa, I (H. de Galdakao, Bizkaia); Valero Santiago, A (H. Clínic de Barcelona); Valido Morales, A (H. Universitario Virgen Macarena, Sevilla); Vaquero Lozano, P (Centro de Especialidades Peña Prieta Hermanos Sangro, Madrid); Vasquez Gambasica, Z (H. Universitario de Getafe, Madrid); Vega Chicote, J (H. Civil de Málaga); Velasco Garrido, J (H. Virgen de La Victoria de Málaga); Viejo Casas, A (Servicio Cantabro de Salud, Cantabria); Villanueva Montes, M (H. San Agustín, Asturias); Villasante Fernández-Montes, C (H. Universitario La Paz, Madrid); Villegas Sánchez, G (H. Torrecardenas, Almería); Zuñil Martín, M (H. Ernest Luch, Zaragoza).

Introduction

IT HAS BEEN ESTIMATED that the degree of compliance with inhaled drug therapy in patients with asthma and chronic obstructive pulmonary disease (COPD) does not surpass 50%.^(1,2) In these patients, non-adherence or inhaler mishandling increases mortality, morbidity, and health care resource utilization.⁽³⁻⁶⁾ Factors related to adherence with inhaled therapy include complexity of the inhalation regimen, peculiarities of inhaler devices, type of inhaled agent, and a variety of patient beliefs and sociocultural and psychological factors.⁽⁷⁾ Therefore, promoting optimal medication adherence is essential to optimize the benefits of treatment. Consequently, measurement of the degree of adherence to inhaled treatment in each individual patient becomes increasingly important in daily practice.

Adherence to medication is mainly assessed by direct anamnesis with the patient, which invariably underestimates the incidence of non-adherence rates. Although standardized patient self-completed questionnaires for measuring medication adherence have been developed,⁽⁸⁻¹⁰⁾ its real use in clinical practice is scarce. Moreover, some features make them inappropriate because they are not adequately validated, not specific for inhaler devices,⁽⁸⁻¹⁰⁾ or only applicable to certain patient populations (asthmatics) or particular inhaled agents (corticosteroids).⁽¹⁰⁾

A further limitation of these questionnaires is a doubtful clinical usefulness to identify barriers to medication adherence and patients at risk of non-adherence. Non-adherent behavior has been broadly classified as erratic, deliberate, and unwitting non-adherence.^(11,12) Up to the present time, however, these typologies have not been reflected in any particular instrument to assess adherence to inhaled therapy. Knowledge of behavior patterns of non-adherence and, particularly, barriers to treatment adherence is clinically relevant to deliver tailored patient education strategies.

With the objective to provide a new questionnaire specifically designed to establish self-reported adherence to inhaler devices and to help clinicians to assess non-adherence barriers related to inhaled therapy in adult asthma and COPD patients, we developed the Test of Adherence to Inhalers (TAI). Initially, a multidisciplinary panel of health care professionals involved in respiratory diseases built, in a pilot study, a test draft version with 12-items. The aim of this study was to validate and to evaluate the psychometric properties of the proposed 12-item TAI.

Materials and Methods

Development, domains, items, and scores of the TAI

The TAI was developed in Spanish and was built in three phases. First, the items that made the first version of the questionnaire were derived from a review of the literature^(8,11,13) and suggestions of the study scientific committee, which lead to a preliminary version that was tested in a group of 10 patients with asthma and/or COPD patients in order to check the intelligibility of the questionnaire. In the second phase, a multidisciplinary panel of 192 investigators composed by pulmonologists, allergists, primary care physicians, and specialized nurses worked together in order to reach a consensus on the items to be included in the questionnaire (based on the Delphi method).⁽¹⁴⁾ In the third phase, a pilot study was

performed with the aim to produce a final version (beta version) of the TAI, prior to the validation study.

The final version of the questionnaire included 12 items (Table 1) with two main domains, the patient (items #1 to #10) and the health professional (items #11 and #12) domain. In fact, the TAI consists of two complementary questionnaires: the 10-items TAI was designed to identify non-adherent patients and to establish the non-adherence level, whereas the 12-items TAI was designed to guide clinically the non-adherence patterns.

In the 10-items TAI, each item scored from 1 to 5 (where 1 was the worst possible score and 5 was the best possible score), with a range from 10 to 50. The 12-items TAI, also includes items #11 and #12 of the health care professional and scored as 1 or 2 (where 1 was bad and 2 was good), with a range from 2 to 4. The latter items were designed to identify two possible causes of unwitting non-adherent behavior. An erratic and deliberate non-adherent behavioral pattern was defined in the presence of scores ≤ 24 for items #1 to #5 and items #6 to #10, respectively. The unwitting pattern was defined in the presence of a score 1 in at least one of the #11 or #12 items of the questionnaire.

In the pilot study, the questionnaire was fulfilled by 50 patients (29 patients with asthma and 21 with COPD), showing a kappa index of 0.858 between independent observers for items #11 and #12.

Study design and participants

Between March 2013 and March 2014, a cross-sectional multicenter study was conducted to validate the TAI instrument. Eligible patients were Spanish speaking men and women, over 18 years of age, treated with inhaled medications for at least 6 months before enrolment. Subjects were consecutively enrolled from the outpatient visits of the participant centers. Patients with inability to fulfill the questionnaire and/or to use inhaler devices were excluded. Asthma and COPD were defined according to the respective current international guidelines.^(15,16) A total of 194 investigators from 139 pulmonology, allergology, and primary care centers participated in the study.

The control group (electronic adherence group) was made up of smartphone user patients with asthma using electronic inhaler devices (Smart-inhalers) (Nexus6 Ltd., Auckland, New Zealand), which silently recorded the date and time of each actuation.⁽¹⁷⁾ These patients were participating in an ongoing study aimed to assess asthma control using electronic medication monitoring, and also were consecutively enrolled from the outpatient visits of the same participating centers. For the purpose of the present study, the inhaler device used (pressurized metered dose inhaler, pMDI, Turbohaler[®] or Diskus[®]) was connected to a specific smart-inhaler.

The study was approved by the Clinical Research Ethics Committee (registration number 2013/8650) of the Hospital Clinic of Barcelona (Spain). Written informed consent was obtained from all participants.

Study procedures

A flow-chart of the study procedures is shown in Figure 1. All study participants attended two consecutive clinical visits 15 days apart. At visit 1, written informed consent was obtained and data on demographics, sociocultural level, and asthma or COPD history were recorded. Also, all patients completed a validated Spanish version of the Morisky-Green

TABLE 1. DESCRIPTION OF TEST OF THE ADHERENCE TO INHALERS (TAI) QUESTIONNAIRE

<i>Patient domain: questions, responses (scores)</i>					Score
1. During the last 7 days, how many times did you forget to take your usual inhalers?					
All (1)	More than half (2)	Approximately a half (3)	Less than half (4)	None (5)	1 to 5
2. Do you forget to take inhalers?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
3. When you feel good about your illness, do you stop taking your inhalers?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
4. When you are on vacation or weekend, do you stop taking your inhalers?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
5. When you are nervous or sad, do you stop taking your inhalers?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
6. Do you stop taking your inhalers because of fear of side effects?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
7. Do you stop taking your inhalers because of considering they are useless to treat your condition?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
8. Do you take fewer inhalations than those prescribed by your doctor?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
9. Do you stop taking your inhalers because you believe they interfere with your everyday or working life?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
10. Do you stop taking your inhalers because you have difficulties to pay them?					
Always (1)	Mostly (2)	Sometimes (3)	Rarely (4)	Never (5)	1 to 5
<i>Health care professional domain: questions, responses (scores)</i>					
11. Does the patient remember the prescribed regimen (dose and frequency)? (checking the medical record)					
No (1)			Yes (2)		1 or 2
12. The technique of using the evaluated inhaler device by the patient is* (checking the inhalation technique)					
With critical mistakes (1)			Without critical mistakes (2)		1 or 2

*Critical mistakes: 1. Pressure metered dose inhalers (pMDIs): do not remove the cover, do not hold the inhaler in a vertical position, firing the device before beginning inspiration, inhalation stopped, inhalation too fast, incorrect insertion of MDI into the inhaler camera, several device firing in the same inhalation, no breath hold after inhalation, cough during inhalation. 2. Dry power inhalers (DPIs): do not open the inhaler, do not prime properly, place the device down after preparation of the dose (before inhalation), blow into the device before inhalation, inhalation not deeply and forcefully, no breath hold after inhalation.

test,^(8,9) and the TAI questionnaire administered. Information related to the feasibility of the TAI was also collected, such as the time needed to complete the questionnaire and if complementary explanations to understand the questions of the items were required.

Clinical asthma control was assessed with the Asthma Control Test (ACT)^(18,19) (an ACT score ≥ 20 identified well-controlled asthma patients), and COPD clinical status was evaluated with the COPD Assessment Test (CAT)⁽²⁰⁾ (CAT ≤ 10 identified mild COPD patients). Spirometry was performed according to the European Respiratory Society/American Thoracic Society guidelines⁽²¹⁾ using the predicted values for Mediterranean population.⁽²²⁾ At visit 2, the Morisky-Green test and TAI were also administered.

Patients in the electronic adherence group also completed the Morisky-Green test and the TAI questionnaire. In these patients, the main measure of electronic adherence was the percentage of inhalations performed correctly between visits 1 and 2. Patients were defined as adherents when $\geq 80\%$ of the doses prescribed were taken, intermediate adherent when took between 50% and 80%, and non-adherent when took $\leq 50\%$.^(10,23) To correct the bias related to a possible error in handling of the electronic inhaler being a new device, the first two actuations recorded were not included in the analysis.

Adherence rates were capped at 100% to avoid dump doses or unintentional actuation.⁽¹³⁾

Sample size calculation and statistical analysis

The sample size was calculated to detect small differences in the TAI scores between visits 1 and 2. Thus, accepting a significance level of 5% and a power of 80%, 870 patients were required to detect differences ≥ 0.2 standard deviations in scores between the two administrations of the questionnaire. A 10% percentage of patients lost to follow-up or with incomplete data were established.

Categorical variables are expressed as absolute and relative frequencies and percentages, and quantitative variables as mean and standard deviation (SD) or median and range (minimum, maximum). To assess the construct validity of the technique of principal component factor analysis with Varimax rotation was used to identify chasing one-dimensional or multidimensional structure of the questionnaire. The appropriateness of factor analysis was verified by measurement of Kaiser-Meyer-Olkin (KMO)^(24,25) and Bartlett's test of sphericity.⁽²⁶⁾ Internal reliability was measured with the Cronbach's alpha coefficient.⁽²⁷⁾

The test-retest reliability of the questionnaire was analyzed using the intraclass correlation coefficient (ICC).²⁸ The




FIG. 1. Flow-chart of the study design and procedures.

criterion validity was made by comparing the percentage of electronic adherence with self-adherence reported in the TAI score. Sensitivity, specificity, positive and negative predictive values were calculated. Cut-offs of the most favorable balance between sensitivity and specificity with the corresponding received operating characteristics (ROC) curves and the area under the curve (AUC) were determined. The Mann-Whitney U test was used for the comparison of quantitative variables and the chi-square (χ^2) test for categorical variables. Correlation between two measures was assessed with the Spearman's rank-order correlation coefficient (ρ). Statistical analysis was performed with Statistical Package for the Social Sciences (SPSS, Chicago, IL, USA) (version 17.0 for Windows). Statistical significance was set at $p < 0.05$.

Results

Characteristics of the study population

A total of 910 patients were included in the self-reported adherence group (500 asthma and 410 COPD) and 99 asthma patients in the electronic adherence group. Socio-demographic data, clinical features and results of pulmonary function tests are shown in Table 2. Patients in both groups were not comparable given that patients in the electronic adherence group were asthmatics, with a higher proportion of women, younger age, better education level and lung function. However, patients with asthma in the self-reported and electronic adherence groups were similar except for a higher percentage of never smokers (70.8% vs. 58.6%, $p=0.016$) and patients who received previous inhaler education (79.5% vs. 63.9%, $p=0.001$) in the self-reported

adherence group. Differences according to age strata or education level were not found.

Psychometric properties of TAI

Scores of the two domains (patient and health care professional) of the TAI are shown in Table 3. The electronic adherence group scores were significantly higher than the self-reported adherence group in the patient domain.

Sampling adequacy for factor analysis assessed with the KMO and the Bartlett's test was appropriate, with a coefficient of 0.905. Factor analysis showed a probable structure of two factors, which explained 51% of the total variance of results. The first factor included items #1 to #10, which was consistent with the patient domain, and the second factor included items #11 and #12 in agreement with the health care professional domain (see Supplementary Table S1; supplementary material is available online at www.liebertpub.com/jamp).

Internal reliability of TAI showed a good inter-item correlation with a Cronbach's alpha coefficient of 0.873 for the 10-items patient domain. The test-retest reliability showed an ICC of 0.883. The mean time needed to fulfill the questionnaire was 6 (5.3) minutes. A total of 151 (15%) patients required supplementary clarifications to complete the patient domain.

In the electronic adherence group, 46 (46.5%) patients were classified as adherents and the remaining 53 (53.5%) as non-adherents. Adherent patients as compared with non-adherent patients showed slightly higher scores in the 10-items patient domain score (48.5 [3.0] vs. 46.8 [4.0]). These differences were statistically significant ($p=0.02$). In relation to the criterion validity, TAI scores correlated with electronic adherence for the 10-items TAI scores ($\rho=0.286$, $P=0.01$).

TABLE 2. SOCIODEMOGRAPHIC, CLINICAL CHARACTERISTICS, AND SPIROMETRIC DATA

Data	Self-reported adherence group (n=910)				P value*
	All patients	COPD (n=410)	Asthma (n=500)	Electronic adherence group (n=99)	
Men	510 (56.0)	340 (82.9)	170 (34.0)	32 (32.3)	0.747
Age, years	58.0 (16.3)	67.8 (9.6)	49.9 (16.3)	47.8 (17.8)	0.209
Education level					
No studies	71 (7.8)	52 (12.7)	19 (3.8)	2 (2.0)	0.224
Primary education	416 (45.7)	240 (58.5)	176 (35.2)	26 (26.3)	
Secondary education	249 (27.4)	76 (18.5)	173 (34.6)	42 (42.4)	
University degree	174 (19.1)	42 (10.2)	132 (26.4)	29 (29.3)	
Clinical data					
Smoking history					
Current smoker	128 (14.1)	91 (22.2)	37 (7.4)	6 (6.1)	0.016
Ex-smoker	414 (45.5)	305 (74.4)	109 (21.8)	35 (35.4)	
Never smoker	368 (40.4)	14 (3.4)	354 (70.8)	58 (58.6)	
Duration of disease, years	13.5 (10.6)	10.5 (8.2)	16.0 (11.6)	17.9 (12.3)	0.151
Previous inhaler education	690 (80.0)	310 (80.5)	380 (79.5)	62 (63.9)	0.001
Asthma Control Test (ACT) ≥20	289 (57.8)	NA	289 (57.8)	66 (66.7)	0.257
COPD assessment test (CAT) ≤10	91 (22.2)	91 (22.2)	NA	NA	
Pulmonary function tests					
FEV ₁ prior to bronchodilator test, mL	2026 (982.8)	1587 (924.1)	2,380.7 (881.3)	2434.9 (981.3)	0.718
FEV ₁ prior to bronchodilator test, %	68.5 (24.5)	52.0 (18.3)	81.8 (20.5)	79.6 (20.6)	0.432
FEV ₁ after bronchodilator test, mL	2123.4 (960.4)	1571.4 (732.8)	2574.5 (886.2)	2548 (919.4)	0.832
FEV ₁ after bronchodilator test, %	74.0 (26.4)	55.9 (20.1)	88.7 (21.3)	86.3 (19.4)	0.211

*Comparison between asthma patients in the self-reported and electronic adherence groups. Data as frequencies and percentages in parentheses unless otherwise stated.

Classification of adherence levels with the 10-items TAI

The sensitivity, specificity, and positive and negative predictive values of the 10-items TAI scores for identifying the groups of adherent, intermediate adherent and non-adherent patients are shown in Table 4. Cut-offs with the most favorable balance between sensitivity and specificity were 50 for adherent patients, 46 to 49 for intermediate adherent patients, and ≤45 for non-adherent patients. The ROC curves for the groups of adherent and non-adherent patients are shown

in Figure 2. The percentages of adherent patients were significantly higher in the electronic adherence group than in the self-reported adherence group (49.5% vs. 37.5%, $p=0.02$) but the distribution of intermediate adherent patients was similar. The rates of non-adherence were also higher in the self-reported adherence group (Fig. 3). A good correlation ($\rho=0.3$, $p=0.01$) was found when adherence levels between self-reported and electronic adherence groups were compared.

Clinically guide of the non-adherence behavior patterns with the 12-items TAI

The 12-items TAI instrument allowed the classification of three non-adherence patterns. In both groups of self-reported and electronic adherence, erratic behavior was the most

TABLE 3. TAI SCORES IN THE STUDY POPULATION

Study groups	Patient domain score (items #1 to #10)	Health care professional domain score (items #11 and #12)
Self-reported adherence group (n=910)		
Mean (SD)	46.1 (5.2)	3.7 (0.6)
Median (minimum; maximum)	48 (18; 50)	4 (2; 4)
Electronic adherence group (n=99)		
Mean (SD)	47.6 (3.7)	3.8 (0.4)
Median (minimum; maximum)	49 (30; 50)	4 (2; 4)
P value*	0.005	0.084

*Comparison between self-reported and electronic adherence groups.

TABLE 4. SENSITIVITY, SPECIFICITY, AND PREDICTIVE VALUES OF THE DIFFERENT CUT-OFFS OF THE 10-ITEMS TAI SCORE

Cut-offs TAI scores*	Sensitivity (%)	Specificity (%)	Predictive value	
			Positive (%)	Negative (%)
50	67.4	66.0	63.3	70.0
49	78.3	50.9	58.1	73.0
48	80.4	43.3	55.2	71.9
47	84.8	30.2	51.3	69.6
46	84.8	26.4	50.0	66.7
45	84.8	22.6	48.8	63.2




FIG. 2. ROC curves for the classification of adherent (AUC=0.7) and non-adherent (AUC=0.6) patients using a cut-off of the 10-items TAI questionnaire of 50 and ≤ 45 , respectively.

frequent, followed by deliberate and unwitting behaviors (Table 5).

Comparison between TAI and the Morisky-Green test

As compared to the Morisky-Green test, TAI showed a slightly better psychometric parameters, with a $\rho=0.286$ for the correlation between 10-items TAI scores and Smart-inhalers records of the electronic group patients, and a

$\rho=0.247$ for the correlation between Smart-inhalers records of the electronic group patients and the Morisky-Green test scores. The kappa statistics was 0.33 for the 10-items of the TAI questionnaire and 0.28 for the Morisky-Green test. Regarding the ability to identify adherent and non-adherent patients, the 10-items TAI showed an intermediate position between the rates observed with the Smart-inhaler electronic devices and the Morisky-Green test (Table 6).




FIG. 3. Overall adherent and non-adherent percentages of patients and adherence levels in the self-reported (n=901) and electronic (n=99) adherence groups with the 10-items TAI.

Discussion

This study shows the validity of a new questionnaire to assess adherence to inhaled medication in patients with asthma or COPD. The TAI instrument possesses good psychometric properties and has been shown not only to be adequate to classify asthma and COPD patients as adherent or non-adherent to inhaled therapy, but also to recognize the predominant pattern of non-adherence behavior in individual patients. Moreover, the questionnaire is short and easy to use for patients of different ages and education levels, providing a cheap, quick, and efficient way of obtaining information on inhaler adherence and non-adherence patterns, applicable to daily practice.

In the present study using a valid qualitative methodology, a total of 12 conditions or barriers to the use of inhalers, which have been related to the control of respiratory diseases in previous studies,⁽²⁹⁻³²⁾ were formed by a consensus of a large group of health care professionals and thereupon, in a large sample of patients. Questionnaires available up to date^(8-10,29) have also assessed some conditions included in the TAI, although in a partial way including forgetfulness,

lack of need of inhaler use, side effects-related concern and availability of the inhaler. However, none of these single barriers has shown predictive validity in the adherence to inhalers.

Since TAI in the extent that covers a wider range of situations (in comparison to its predecessors) and has been shown its viability in the health care setting, it may be a valuable tool for clinical use. Also, a novel aspect of the questionnaire is the inclusion of health care professionals' assessment of the patient's ability with the use of his/her inhaler. The patient competence in handling the device is a prerequisite for adherence. Therefore, based on the methodology used in the development of the TAI, the 12 conditions assessed by the instrument are clinically relevant to determine the level of adherence to inhalers.

The large study population of patients with COPD and asthma recruited by almost 200 specialists in different health care settings allowed a study of a representative sample of the patients with asthma and COPD, their treatment, and, therefore the main barriers modulating patient-physician

TABLE 5. NON-ADHERENCE BEHAVIOR PATTERNS ORIENTED WITH THE 12-ITEMS TAI

Non-adherence pattern*	Self-reported adherence group (n=910)	Electronic adherence group (n=99)
Erratic	530 (58.2)	48 (48.5)
Deliberate	376 (41.3)	26 (26.3)
Unwitting	242 (26.6)	19 (19.2)

*Frequency of non-adherent patterns is higher than 100% because more than one non-adherent pattern may be present in the same patient.

TABLE 6. ABILITY TO IDENTIFY ADHERENT AND NON-ADHERENT PATIENTS WITH SMART-INHALER DEVICE, 10-ITEMS TAI, AND MORISKY-GREEN TEST IN ELECTRONIC ADHERENCE GROUP

	Smart-inhaler electronic device	10-items TAI questionnaire	Morisky-Green test
Adherent patients, n (%)	46 (46.5)	49 (49.5)	52 (52.5)
Non-adherent patients, n (%)	53 (53.5)	50 (50.5)	47 (47.5)
Total patients	99	99	99

relationship, satisfaction, and health care system functioning that may affect adherence. Accordingly, the study sample was adequate to assess adherence to inhalers in both diseases from an overall perspective.

On the other hand, the inclusion of electronic devices provided reliable data on adherence in a group of participants. This objective measure of adherence, which is unusual in validation studies of other questionnaires probably because of the high cost, guaranteed robustness of the validation process. Scores of the 10-items and 12-items TAI were directly and positively correlated with data recorded with the Smart-inhalers, and differences between patients classified as adherents and non-adherents were also statistically significant. The observation that correlations, although statistically significant, were somewhat low may be explained by the fact that self-reported adherence is less reliable than electronic measures,⁽³³⁾ and the lower sample size in the electronic adherence group which probably prevented to achieve better correlation levels.

The differences in sociodemographic and clinical characteristics between patients in the electronic adherence group (higher percentage of women and education level) and the self-reported adherence group (combination of asthma and COPD patients, with a lower percentage of women and education level) do not question the validation of TAI. Results obtained in the electronic adherence group will be potentially generalizable to a similar population and also be subjected to similar adherence-related difficulties or barriers. It is possible that clinical and sociodemographic characteristics of the electronic adherence group may be the reason for significantly better TAI scores in this group as compared to the self-reported adherence group. Also, the large number of patients in the self-report adherence group versus the electronic adherence group probably determined that statistical significance could be easily reached. Despite these considerations, findings in the electronic adherence group provide solid evidence of the capacity of TAI to identify adherence to inhalers.

In relation to the electronic device monitoring, it should be noted that information recorded by the electronic devices not only includes whether the patient used the inhaler for a certain number of times, but also the hours at which the device was used during the "evaluation" days (in our study the 14 days between visits 1 and 2). This eliminates the possibility of dumping occurring immediately prior to the control visit because it would be registered that the patient used the inhaler on multiple occasions in that day and not in the expected mode (several times during the 14 days period). On the other hand, first readings of smart-inhalers on visit 1 were discarded to exclude the possible impact of the patient's training effect.

According to factor analysis of the two main components, different criteria for scoring these two dimensions were chosen. Clinical practice experience and the results of numerous studies^{34,35} indicate that knowledge/recall of the prescription (item #11) and competence in using the inhaler (item #12) are prerequisites for adherence. Consequently, they play a differential role in adherence-related barriers, which logically also appeared statistically as a differential factor. This finding suggests that TAI may be used as a questionnaire of two measures with different applications: to identify adherence (10-items TAI, patient domain) and to have a clinical indication of the non-adherence behavior pattern (12-items TAI, both patient and health care professional domains).

The unidimensional structure of the 10-items TAI reflects the complexity of the adherence phenomenon. Studies in patients with respiratory disorders and other diseases^{36,37} have shown that adherence is a particular complex issue, in which different barriers that compromise adherence have a low predictive capacity by themselves but combine and modify during the process of disease. In this respect, results of the present study show that when patients are classified by responses suggesting an erratic, deliberate, or unwitting non-adherence behavior pattern, the possibility to identify statistically different types of non-adherent patients was compromised.

This consideration, however, does not affect the internal validity of the instrument or the clinical usefulness of TAI. On the contrary, the percentages of non-adherence regarding the total number of items as well as grouped by the profile of non-adherence are sufficiently indicative of the importance of the problem and the value of the qualitative analysis of the items of each of the three non-adherence behaviour pattern. Accordingly, it is possible to identify quickly, reliably and objectively situations that may compromise adherence to inhaler devices that might otherwise go unnoticed in routine clinical practice.

There are some limitations of the study that deserves a comment. First, the lack of an electronic control group for COPD patients. Second, the weight of each adherence-related barrier according to different clinical and sociodemographic characteristics of patients with respiratory diseases and the inter-relationship among barriers were not assessed. Internal validity and clinical relevance of the study, however, are not affected by these limitations. In further studies, the Rash model approach as used by Kleppe et al.⁽³⁸⁾ in the development of a Probabilistic Medication Adherence Scale (ProMAS) tested in 370 elderly patients receiving medication for chronic conditions may be suggested to assess the construct validity of TAI.

In conclusion, TAI is a new questionnaire, specifically developed to identify non-adherence and specific adherence barriers involved in inhaled therapy. The study demonstrated the good psychometric properties of the questionnaire and validated their usefulness in the clinical setting. This could bring a new tool, to improve the patient's adherence to inhaler devices, according to their specific non-adherence pattern after implement tailored strategies.

Acknowledgment

The authors are grateful to all study participants. We also thank Marta Pulido for editing the manuscript and editorial assistance, and Montserrat Falgueras and Manuel Lora for their support. The fees of medical editing and statistical analysis were supported by Chiesi Spain.

This study was funded by the Integrated Research Asthma Program (PII Asthma) together with the Integrated Research COPD Program (PII COPD) of the Spanish Respiratory Society (SEPAR). Unconditional funding was provided by Chiesi, who did not participate in data collection, interpretation of the results, or writing of the manuscript.

Author Disclosure Statement

Vicente Plaza, in the last 3 years, received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, and Pfizer; and acted as a consultant for Mundipharma, Orion, and Teva. He received help assistance

to meeting travel from Boehringer-Ingelheim and Chiesi, and received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Chiesi, Menarini, and Merck.

Concepción Fernández-Rodríguez, in the last 3 years, received honoraria for speaking at sponsored meetings from Chiesi and Merck, and received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as from Chiesi.

Carlos Melero, in the last 3 years, received honoraria for speaking at sponsored meetings from AstraZeneca, Almirall, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma Novartis, Pfizer, and Teva, and was a consultant for Mundipharma and Novartis. He received funding/grant support for research projects from Novartis, AstraZeneca, Vifor Pharma, Chiesi, and Boehringer-Ingelheim.

Borja G. Cosío, in the last 3 years, received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer-Ingelheim, Menarini, Chiesi, GlaxoSmithKline, and Pfizer, and was a consultant for GSK and Novartis. He received help assistance to meeting travel from GSK and Chiesi, and received funding/grant support for research projects from a variety of Government agencies and not-for-profit foundations, as well as, Chiesi, Menarini and Boehringer-Ingelheim.

Luís Manuel Entrenas, in the last 3 years, received honoraria for speaking at sponsored meetings from AstraZeneca, Almirall, Boehringer-Ingelheim, Chiesi, Esteve, Ferrer, GlaxoSmithKline, Merck, Mundipharma, Novartis, Pfizer, and Teva, was a consultant for Mundipharma and Novartis, and received funding/grant support for research projects from Novartis.

Luis Pérez de Llano, in the last 3 years, received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer-Ingelheim, Menarini, Chiesi, GlaxoSmithKline, Teva, Almirall, Mundipharma, Esteve, Novartis, and Pfizer, was a consultant for Mundipharma, Pfizer, Ferrer, and Novartis. He received help assistance to meeting travel from GSK and Novartis, and funding/grant support for research projects from a SEPAR and SERGAS.

Fernando Gutiérrez-Pereyra declares that no conflicts of interest exist.

Eduard Tarragona received a stipend as a Medical Advisor from Chiesi.

Rosa Palomino received a stipend as a specialist in statistics from GOC Networking.

Antolín López-Viña, in the last 3 years, received honoraria for speaking at sponsored meetings from Chiesi, GSK, Boehringer-Ingelheim, Novartis and Pfizer; was a consultant for Pfizer, Boehringer-Ingelheim and Novartis, received help assistance to meeting travel from Boehringer-Ingelheim, Novartis and Chiesi, and received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Chiesi and Menarini.

References

1. Bozek A, and Jarzab J: Adherence to asthma therapy in elderly patients. *J Asthma*. 2010;47:162–165.
2. Cecere LM, Slatore CG, Uman JE, Evans LE, Udris EM, Bryson CL, and Au DH: Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). *COPD*. 2012;9:251–258.
3. Boulet LP, Vervloet D, Magar Y, and Foster JM: Adherence: The goal to control asthma. *Clin Chest Med*. 2012;33:405–417.
4. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, and Jones PW: Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax*. 2009;64:939–943.
5. Klok T, Kaptein AA, Duiverman EJ, and Brand PL: It's the adherence, stupid (that determines asthma control in preschool children)! *Eur Respir J*. 2014;43:783–791.
6. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, and Neri M; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri: Inhaler mishandling remains common in real life and is associated with reduced disease control. *Respir Med*. 2011;105:930–938.
7. Rau JL: Determinants of patient adherence to aerosol regimen. *Respir Care*. 2005;50:1346–1356.
8. Morisky DE, Green LW, and Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care* 1986; 24: 67–74.
9. Val Jiménez A, Amorós Ballester G, Martínez Visa P, Fernández Ferré ML, and León Sanromà M: Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. *Aten Primaria*. 1992;10:767–770.
10. Cohen JL, Mann DM, Wisnivesky JP, Home R, Leventhal H, Musumeci-Szabó TJ, and Halm EA: Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: The Medication Adherence Report Scale for Asthma. *Ann Allergy Asthma Immunol*. 2009;103:325–331.
11. Singh M, and Kansra S: Adherence issues in asthma. *Indian Pediatr*. 2006;43:1050–1055.
12. Rand CS: Adherence to asthma therapy in the preschool child. *Allergy*. 2002;57:48–57.
13. Rand CS, and Wise RA: Measuring adherence to asthma medication regimens. *Am J Respir Crit Care Med* 1994;149: S69–S78.
14. Dalkey NC: *The Delphi Method: An Experimental Study of Group Opinion*. Santa Monica, CA: Rand Corporation, 1969.
15. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014: Available from: <http://www.ginasthma.org/>. Last access: 10/3/14.
16. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. Available from: <http://www.goldcopd.org/>. Last access: 10/3/14.
17. Burgess SW, Wilson SS, Cooper DM, Sly PD, and Devadason SG: In vitro evaluation of an asthma dosing device: The smart-inhaler. *Respir Med*. 2006;100:841–845.
18. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, and Pendergraft TB: Development of the asthma control test: A survey for assessing asthma control. *J Allergy Clin Immunol*. 2004;113:59–65.
19. Vega JM, Badia X, Badiola C, López-Viña A, Olaguíbel JM, Picado C, Sastre J, and Dal-Ré R: Validation of the Spanish version of the Asthma Control Test (ACT). *J Asthma*. 2007;44:867–872.
20. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluña JJ, van der Molen T, Adamek L, and Banik N: Properties of the COPD assessment test in a cross-sectional European study. *Eur Respir J*. 2011;38:29–35.
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D,

- Pedersen OF, Pellegrino R, Viegi G, and Wanger J: Standardisation of spirometry. *Eur Respir J*. 2005;26:319–338.
22. Roca J, Sanchis J, Agusti-Vidal A, Segarra F, Navajas D, Rodriguez-Roisin R, Casan P, and Sans S: Spirometric reference values from a Mediterranean population. *Bull Eur Physiopathol Respir*. 1986;22:217–224.
 23. Rand CS, Wise RA, Nides M, Simmons MS, Bleecker ER, Kusek JW, Li VC, and Tashkin DP: Metered-dose inhaler adherence in a clinical trial. *Am Rev Respir Dis*. 1992;146:1559–1564.
 24. Kaiser HF: A second-generation Little Jiffy. *Psychometrika*. 1970;35:401–415.
 25. Kaiser HF, and Rice J: Little Jiffy Mark IV. *Educ Psychol Meas*. 1974;34:111–117.
 26. Bartlett M: Tests of significance in factor analysis. *Br J Psychol*. 1950;3:77–85.
 27. Cronbach LJ: Coefficient alpha and the internal structure test. *Psychometrika*. 1951;16:297.
 28. Prieto L, Lamarca R, and Casado A: Assessment of the reliability of clinical findings: The intraclass correlation coefficient. [Article in Spanish]. *Med Clin (Barc)*. 1998;110:142–145.
 29. Brooks CM, Richards JM, Kohler CL, Soong SJ, Martin B, Windsor RA, and Bailey WC: Assessing adherence to asthma medication and inhaler regimens: A psychometric analysis of adult self-report scales. *Med Care*. 1994;32:298–307.
 30. Erickson SR, Coombs JH, Kirking DM, and Azimi AR: Compliance from self-reported versus pharmacy claims data with metered-dose inhalers. *Ann Pharmacother*. 2001;35:997–1003.
 31. Hahn SR, Park J, Skinner EP, Yu-Isenberg KS, Weaver MB, Crawford B, and Flowers PW: Development of the ASK-20 adherence barrier survey. *Curr Med Res Opin*. 2008;24:2127–2138.
 32. McHorney CA, Victor Spain C, Alexander CM, and Simmons J: Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: A prospective analysis of data from pharmacy claims. *Clin Ther*. 2009;31:2584–2607.
 33. Nikander K, Pearce LJ, Smith NJ, and Pritchard JN: The impact of electronic monitors on patients' adherence to inhaled medications. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, and Young PM, editors. *Respiratory Drug Delivery 2012*. River Grove IL: Davis Healthcare International Publishing, pp. 673–678. Available at: <http://www.rddonline.com/publications/articles/article.php?ArticleID=1761&return=1>. Last access: 10/3/14.
 34. Baddar S, Jayakrishnan B, and Al-Rawas OA: Asthma control: Importance of compliance and inhaler technique assessments. *J Asthma*. 2014;51:429–434.
 35. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, and Crompton GK: Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respir Med*. 2008;102:593–604.
 36. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, Ownby DR, and Johnson CC: Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. *J Allergy Clin Immunol*. 2004;114:1288–1293.
 37. Cramer JA: A systematic review of adherence with medications for diabetes. *Diabetes Care*. 2004;27:1218–1224.
 38. Kleppe M, Lacroix J, Ham J, and Midden C: The development of the ProMAS: A Probabilistic Medication Adherence Scale. *Patient Prefer Adherence*. 2015;9:355–367.

Received on February 9, 2015
in final form, May 22, 2015

Reviewed by:
Sunalene Devadason
John Pritchard

Address correspondence to:
Vicente Plaza, MD, PhD
Servei de Pneumologia
Hospital de la Santa Creu i Sant Pau
C/ Sant Antoni M. Claret 167
E-08025 Barcelona
Spain

E-mail: vplaza@santpau.cat